Sara A Harper1, John R Bassler2, Sujitha Peramsetty3, Youfeng Yang4, Lisa M Roberts5, Devin Drummer6, Robert T Mankowski7, Christiaan Leeuwenburgh8, Karina Ricart9, Rakesh P Patel10, Marcas M Bamman11, Stephen D Anton12, Byron C Jaeger13, Thomas W Buford14. 1. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Kinesiology and Health Science Department, Utah State University, Logan, UT, USA; Sorenson Legacy Foundation Center for Clinical Excellence, Utah State University, Logan, UT, USA. Electronic address: sara.harper@usu.edu. 2. Department of Biostatistics, University of Alabama at Birmingham, AL, USA. Electronic address: jbassle1@uab.edu. 3. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Integrative Center for Aging Research, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: gperam@uab.edu. 4. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Integrative Center for Aging Research, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: youfengyang@uabmc.edu. 5. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Integrative Center for Aging Research, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: lmroberts@uabmc.edu. 6. Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: drummerd@uab.edu. 7. Department of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA. Electronic address: r.mankowski@uflu.edu. 8. Department of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA. Electronic address: cleeuwen@flu.edu. 9. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: karinaricart@uabmc.edu. 10. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: rakeshpatel@uabmc.edu. 11. Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: mbamman@uab.edu. 12. Department of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA. Electronic address: santon@ufl.edu. 13. Department of Biostatistics, University of Alabama at Birmingham, AL, USA. Electronic address: bcjaeger@uab.edu. 14. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Integrative Center for Aging Research, University of Alabama at Birmingham, Birmingham, AL, USA; UAB Nathan Shock Center on the Basic Biology of Aging, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: twbuford@uabmc.edu.
Abstract
PURPOSE: To evaluate the safety and feasibility of combining exercise (EX) and resveratrol to treat older adults with physical function limitations. METHODS: Three-arm, two-site pilot randomized, controlled trial (RCT) for community-dwelling adults (N = 60), 71.8 ± 6.3 years of age with functional limitations. Participants were randomized to receive either 12 weeks of (1) EX + placebo [EX0], (2) EX + 500 mg/day resveratrol [EX500], or (3) EX + 1000 mg/day resveratrol [EX1000]. EX consisted of two sessions a week for 12 weeks of center-based walking and whole-body resistance training. Safety was assessed through adverse events and feasibility through exercise session and supplement (placebo, or resveratrol) protocol adherence. Outcome measures included a battery of indices of physical function as well as skeletal muscle mitchondrial function. Data were adjusted for age and gender using the Intent-To-Treat approach. RESULTS: Adverse event frequency and type were similar between groups (n = 8 EX0, n = 12 EX500, and n = 7 EX1000). Overall, 85% of participants met the supplement adherence via pill counts while 82% met the exercise session adherence. Adjusted within group mean differences (95% confidence interval) from week 0 to 12 for gait speed ranged from -0.04 (EX0: -0.1, 0.03) m/s to 0.04 (EX1000: -0.02, 0.11) and the six-minute walk test mean differences were 9.45 (EX0: -9.02, 27.7), 22.9 (EX500: 4.18, 41.6), and 33.1 (EX1000: 13.8, 52.4) meters. Unadjusted mean differences for citrate synthase were -0.80 (EX0: -15.45, 13.84), -1.38 (EX500: -12.16, 9.39), and 7.75 (EX1000: -4.68, 20.18) mU/mg. COX activity mean within group changes ranged from -0.05 (EX0) to 0.06 (EX500) k/s/mg. Additional outcomes are detailed in the text. CONCLUSION: The pilot RCT indicated that combined EX + resveratrol was safe and feasible for older adults with functional limitations and may improve skeletal muscle mitochondrial function and mobility-related indices of physical function. A larger trial appears warranted and is needed to formally test these hypotheses.
PURPOSE: To evaluate the safety and feasibility of combining exercise (EX) and resveratrol to treat older adults with physical function limitations. METHODS: Three-arm, two-site pilot randomized, controlled trial (RCT) for community-dwelling adults (N = 60), 71.8 ± 6.3 years of age with functional limitations. Participants were randomized to receive either 12 weeks of (1) EX + placebo [EX0], (2) EX + 500 mg/day resveratrol [EX500], or (3) EX + 1000 mg/day resveratrol [EX1000]. EX consisted of two sessions a week for 12 weeks of center-based walking and whole-body resistance training. Safety was assessed through adverse events and feasibility through exercise session and supplement (placebo, or resveratrol) protocol adherence. Outcome measures included a battery of indices of physical function as well as skeletal muscle mitchondrial function. Data were adjusted for age and gender using the Intent-To-Treat approach. RESULTS: Adverse event frequency and type were similar between groups (n = 8 EX0, n = 12 EX500, and n = 7 EX1000). Overall, 85% of participants met the supplement adherence via pill counts while 82% met the exercise session adherence. Adjusted within group mean differences (95% confidence interval) from week 0 to 12 for gait speed ranged from -0.04 (EX0: -0.1, 0.03) m/s to 0.04 (EX1000: -0.02, 0.11) and the six-minute walk test mean differences were 9.45 (EX0: -9.02, 27.7), 22.9 (EX500: 4.18, 41.6), and 33.1 (EX1000: 13.8, 52.4) meters. Unadjusted mean differences for citrate synthase were -0.80 (EX0: -15.45, 13.84), -1.38 (EX500: -12.16, 9.39), and 7.75 (EX1000: -4.68, 20.18) mU/mg. COX activity mean within group changes ranged from -0.05 (EX0) to 0.06 (EX500) k/s/mg. Additional outcomes are detailed in the text. CONCLUSION: The pilot RCT indicated that combined EX + resveratrol was safe and feasible for older adults with functional limitations and may improve skeletal muscle mitochondrial function and mobility-related indices of physical function. A larger trial appears warranted and is needed to formally test these hypotheses.
Authors: Alan M Jette; Stephen M Haley; Wendy J Coster; Jill T Kooyoomjian; Suzette Levenson; Tim Heeren; Jacqueline Ashba Journal: J Gerontol A Biol Sci Med Sci Date: 2002-04 Impact factor: 6.053
Authors: Jessica L Fry; Leona Al Sayah; Robert M Weisbrod; Isabelle Van Roy; Xiang Weng; Richard A Cohen; Markus M Bachschmid; Francesca Seta Journal: Hypertension Date: 2016-07-18 Impact factor: 10.190
Authors: Vernon W Dolinsky; Kelvin E Jones; Robinder S Sidhu; Mark Haykowsky; Michael P Czubryt; Tessa Gordon; Jason R B Dyck Journal: J Physiol Date: 2012-04-02 Impact factor: 5.182
Authors: Milan Chang; Jiska Cohen-Mansfield; Luigi Ferrucci; Suzanne Leveille; Stefano Volpato; Nathalie de Rekeneire; Jack M Guralnik Journal: J Am Geriatr Soc Date: 2004-12 Impact factor: 5.562
Authors: Jessica L Fetterman; Monica Holbrook; David G Westbrook; Jamelle A Brown; Kyle P Feeley; Rosa Bretón-Romero; Erika A Linder; Brittany D Berk; Robert M Weisbrod; Michael E Widlansky; Noyan Gokce; Scott W Ballinger; Naomi M Hamburg Journal: Cardiovasc Diabetol Date: 2016-03-31 Impact factor: 9.951
Authors: Cory M Dungan; Camille R Brightwell; Yuan Wen; Christopher J Zdunek; Christine M Latham; Nicholas T Thomas; Alyaa M Zagzoog; Benjamin D Brightwell; Georgia L VonLehmden; Alexander R Keeble; Stanley J Watowich; Kevin A Murach; Christopher S Fry Journal: Function (Oxf) Date: 2022-05-23
Authors: Arlek González-Jamett; Walter Vásquez; Gabriela Cifuentes-Riveros; Rafaela Martínez-Pando; Juan C Sáez; Ana M Cárdenas Journal: Biomedicines Date: 2022-02-21